OFLOXACIN - A REAPPRAISAL OF ITS ANTIMICROBIAL ACTIVITY, PHARMACOLOGY AND THERAPEUTIC USE

被引:85
作者
TODD, PA [1 ]
FAULDS, D [1 ]
机构
[1] ADIS INT LTD,41 CENTORIAN DR,AUCKLAND 10,NEW ZEALAND
关键词
D O I
10.2165/00003495-199142050-00008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ofloxacin is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. In vitro it has a broad spectrum of activity against aerobic Gram-negative and Gram-positive bacteria, although it is poorly active against anaerobes. Ofloxacin, unlike most other broad spectrum antibacterial drugs, can be administered orally as well as intravenously. Penetration into body tissues and fluids is highly efficient. Clinical trials with orally and intravenously administered ofloxacin have confirmed its potential for use in a wide range of infections, where it has generally proved as effective as standard treatments. Ofloxacin is well tolerated, and in comparison with other available fluoroquinolones is less likely to cause clinically relevant drug interactions. Ofloxacin thus offers a valuable oral treatment (with an option for intravenous administration if necessary) for use in a wide range of clinical infections, but with a particular advantage in more severe or chronic infections when recourse to parenteral broad spectrum agents would normally be required, thereby providing cost savings and additionally allowing outpatient treatment.
引用
收藏
页码:825 / 876
页数:52
相关论文
共 483 条
[1]  
ACOCELLA G, 1990, J ANTIMICROB CHEMOTH, V23, P433
[2]  
AHMEDJUSHUF IA, 1988, GENITOURIN MED, V64, P14
[3]  
AKALIN HE, 1989, REV INFECT DIS, V11, pS1152
[4]  
AKHTAR MA, 1989, REV INFECT DIS, V11, pS1193
[5]  
ALEGRE J, 1990, EUR RESPIR J, V3, P238
[6]   DEVELOPMENT OF CIPROFLOXACIN RESISTANCE IN BRUCELLA-MELITENSIS [J].
ALSIBAI, MB ;
QADRI, SMH .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 25 (02) :302-303
[7]  
[Anonymous], 1984, CHEMOTHERAPY, V32, P118
[8]  
AOKI Y, 1991, CHEMOTHERAPY-TOKYO, V39, P570
[9]   SUSCEPTIBILITY OF 310-NONFERMENTATIVE GRAM-NEGATIVE BACTERIA TO AZTREONAM, CARUMONAM, CIPROFLOXACIN, OFLOXACIN AND FLEROXACIN [J].
APPELBAUM, PC ;
SPANGLER, SK ;
TAMARREE, T .
CHEMOTHERAPY, 1988, 34 (01) :40-45
[10]   SUSCEPTIBILITY OF PENICILLIN-SENSITIVE AND PENICILLIN-RESISTANT STRAINS OF STREPTOCOCCUS-PNEUMONIAE TO NEW ANTIMICROBIAL AGENTS, INCLUDING DAPTOMYCIN, TEICOPLANIN, CEFPODOXIME AND QUINOLONES [J].
APPELBAUM, PC ;
SPANGLER, SK ;
CROTTY, E ;
JACOBS, MR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1989, 23 (04) :509-516